Insulin inhalation - Dance Biopharm

Drug Profile

Insulin inhalation - Dance Biopharm

Alternative Names: Dance 501; Dance-01

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dance Pharmaceuticals
  • Developer Dance Biopharm
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 16 Oct 2017 Dance Biopharm plans a phase I trial for Insulin inhalation in Healthy volunteers in the USA (NCT03307512)
  • 29 Aug 2017 Dance Biopharm acquires Harmony Plus Holdings Limited, along with the Asia License of Inhaled insulin from Harmony Plus Holdings
  • 15 Feb 2016 This programme is still active
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top